CMA “ignored” evidence in excessive pricing case, Pfizer says
The UK’s Competition and Markets Authority “ignored” evidence in its decision that two drug companies’ prices were excessive, their defence counsel have argued.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10